Maine Medicine Weekly Update - 08/12/2019  (Plain Text Version)

Return to Graphical Version

 

In this issue:
IN THE SPOTLIGHT
•  MMA's 166th Annual Session in Bar Harbor September 6-8
•  Surprise Billing Legislation Being Considered in Congress
•  Proposed Medicare Fee Schedule Changes
•  Recent Study Suggests CV Risk Reduction From Continuing Statins After 75
•  This Week's Public Health Updates from the AMA
•  10th Annual Silent Auction to Be Held at Annual Session
•  MICIS Individual Academic Detailing Sessions on Opioid Topics
•  United States Census 2020
129th MAINE LEGISLATURE
•  MMA Legislative Calls Finished for the Session
UPCOMING EVENTS
•  Upcoming Specialty Society Meetings
•  Complex Mental and Behavioral Health Needs of Maine Youth - August 16
•  Quality Counts: Rapid Induction Starting in the ED (RISE) Training, ECHO Program
•  Obesity Medicine: There is no 'one size fits all' - Monthly Lecture Series Beginning September 18th
•  Maine Concussion Management Initiative (MCMI) Training Program - October 9
•  MMA partners with the Maine Suicide Prevention Program to offer training for clinicians.
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Outpatient Internal Medicine Physician Bangor, Maine
•  BC/BE Family Medicine or Internal Medicine Physician
•  Northern Light Sebasticook Valley Hospital seeks a BC/BE General Surgeon
•  Family Medicine Opportunity in Beautiful Western Maine
•  Physician Director of Primary Care
•  Family Medicine Specialist or an Internist
VOLUNTEER OPPORTUNITIES
•  Opportunities at the VA for Volunteer Physicians
•  Volunteer Opportunity with Partners for World Health

 

Recent Study Suggests CV Risk Reduction From Continuing Statins After 75

A recent study suggests potential cardiovascular risk reduction associated with continuing statin therapy after the age of 75 years in persons already taking these drugs for primary prevention. However, due to the observational nature of this study, residual confounding cannot be excluded. Future studies, including interventional randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

 

A recent European study suggests potential cardiovascular risk reduction associated with continuing statin therapy after the age of 75 years in persons already taking these drugs for primary prevention. However, due to the observational nature of this study, residual confounding cannot be excluded. Future studies, including interventional randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

The role of statin therapy in primary prevention of cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. The researchers assessed the effect of statin discontinuation on cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. The study itself may be read here: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz458/5540819